OIS-Generic-Author-Image-MALE

Heather Johnson

Contributing Writer

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma

October 6 2020

Opthea’s Activity Leads to IPO

Opthea, the Australia-based biopharma developing a novel therapy to treat exudative retinal diseases, closed out a busy summer with a US Securities and Exchange Commission ...
Read More

September 8 2020

Kubota’s Smart Glasses Aim to Slow Myopia Progression

They won’t help you search the Internet, but Kubota Vision’s glasses may help slow the progression of myopia, and possibly even prevent the condition when ...
Read More

September 1 2020

The COVID Effect: Q2 Was Tough, Q3 Is Looking Up

Ophthalmology drugs, particularly drugs associated with surgeries and retinal disease, took a beating in Q2 because of COVID-19 disruptions. Things may be looking up for ...
Read More
Emerging Glaucoma Devices See Beyond IOP

May 27 2020

Emerging Glaucoma Devices See Beyond IOP

The glaucoma space has been dominated by a host of products designed to lower intraocular pressure (IOP) – minimally invasive glaucoma surgery (MIGS) devices and ...
Read More
9 Steps to Launching a Product

March 3 2020

9 Steps to Launching a Product

Editor's Note: The FDA just approved Allergan's Durysta (bimatoprost implant) 10 mcg for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension on ...
Read More
Glaucoma 360: Promising data as the industry considers value

February 12 2020

Glaucoma 360: Promising data as the industry considers value

“Innovation remains the largest driver of healthcare cost increase,” said David Parke II, MD, American Academy of Ophthalmology CEO, during the Glaucoma Research Foundation’s (GRF) ...
Read More
Will a New Drug Using Cannabinoids Achieve a Breakthrough for Glaucoma?

March 19 2019

Will a New Drug Using Cannabinoids Achieve a Breakthrough for Glaucoma?

SAN FRANCISCO – Nemus Bioscience, a biopharmaceutical company based in Southern California, came to the Glaucoma 360 New Horizons Forum here in February to make ...
Read More
How Glaucoma Device Companies Raise Funding to Navigate ‘Death Valley’

March 6 2019

How Glaucoma Device Companies Raise Funding to Navigate ‘Death Valley’

SAN FRANCISCO – At the Glaucoma 360 New Horizons Forum here, Emmett Cunningham, Jr., MD, PhD, moderating a panel on financing for emerging glaucoma device ...
Read More
Reimbursement Hurdles in Glaucoma Space

February 20 2019

Parsing the Challenges of Reimbursement in the Glaucoma Space: Drug and Device Developers Address Elephant in the Room

SAN FRANCISCO – When it comes to securing reimbursement models, ophthalmic device and drug developers are facing mounting pressure. Payers are demanding more evidence on ...
Read More
Glaucoma Genetics: State of the Science

February 5 2019

The State of the Art of Glaucoma Genetics

SAN FRANCISCO – Advances in glaucoma genetics potentially hold the key to new therapies for prevention, early detection, and a cure, researcher Janey L. Wiggs, ...
Read More